Anti-C5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis

被引:127
作者
Laudes, IJ
Chu, JC
Sikranth, S
Huber-Lang, M
Guo, RF
Riedemann, N
Sarma, JV
Schmaier, AH
Ward, PA
机构
[1] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA
关键词
D O I
10.1016/S0002-9440(10)61133-9
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Sepsis and trauma are the two most common causes of disseminated intravascular coagulation and multiple organ dysfunction syndrome. Both disseminated intravascular coagulation and the systemic inflammatory response syndrome often lead to multiple organ dysfunction syndrome. The current studies have evaluated the relationship between the anaphylatoxin, C5a, and changes in the coagulation/fibrinolytic systems during the cecal ligation and puncture (CLP) model of sepsis in rats. CLP animals treated with anti-C5a had a much improved number of survivors (63%) compared to rats treated with pre-immune IgG (31%). In CLP rats treated with pre-immune IgG there was clearly increased procoagulant activity with prolongation of the activated partial thromboplastin time and prothrombin time, reduced platelet counts, and increased levels of plasma fibrinogen. Evidence for thrombin formation was indicated by early consumption of factor VII:C, subsequent consumption of factors XI:C and IX:C and anti-thrombin and increased levels of the thrombin-anti-thrombin complex and D-dimer. Limited activation of fibrinolysis was indicated by reduced plasma levels of plasminogen and increased levels of tissue plasminogen activator and plasminogen activator inhibitor. Most of these parameters were reversed in CLP rats that had been treated with anti-C5a. Production of C5a during sepsis may directly or indirectly cause hemostatic defects that can be reduced by blockade of C5a.
引用
收藏
页码:1867 / 1875
页数:9
相关论文
共 51 条
[1]  
ALEXANDER JW, 1979, SURGERY, V86, P94
[2]  
Baudo F, 2000, 5TH WORLD CONGRESS ON TRAUMA, SHOCK, INFLAMMATION AND SEPSIS, P835
[3]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[4]   INTERLEUKIN-1 (IL-1) INDUCES BIOSYNTHESIS AND CELL-SURFACE EXPRESSION OF PROCOAGULANT ACTIVITY IN HUMAN VASCULAR ENDOTHELIAL-CELLS [J].
BEVILACQUA, MP ;
POBER, JS ;
MAJEAU, GR ;
COTRAN, RS ;
GIMBRONE, MA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1984, 160 (02) :618-623
[5]   TOWARD AN EPIDEMIOLOGY AND NATURAL-HISTORY OF SIRS (SYSTEMIC INFLAMMATORY RESPONSE SYNDROME) [J].
BONE, RC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (24) :3452-3455
[6]  
Carey MJ, 1998, AM J HEMATOL, V59, P65, DOI 10.1002/(SICI)1096-8652(199809)59:1<65::AID-AJH13>3.0.CO
[7]  
2-0
[8]  
CARSON SD, 1990, BLOOD, V76, P361
[9]   THE ROLE OF PLASMA PROTEASES IN SEPTIC SHOCK [J].
COLMAN, RW .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (18) :1207-1209
[10]   CULTURED HUMAN-ENDOTHELIAL CELLS GENERATE TISSUE FACTOR IN RESPONSE TO ENDOTOXIN [J].
COLUCCI, M ;
BALCONI, G ;
LORENZET, R ;
PIETRA, A ;
LOCATI, D ;
DONATI, MB ;
SEMERARO, N .
JOURNAL OF CLINICAL INVESTIGATION, 1983, 71 (06) :1893-1896